BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu HJ, Chu PY. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Int J Mol Sci 2019;20:E4154. [PMID: 31450710 DOI: 10.3390/ijms20174154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Jiang X, Xing L, Chen Y, Qin R, Song S, Lu Y, Xie S, Wang L, Pu H, Gui X, Li T, Xu J, Li J, Jia S, Lu D. CircMEG3 inhibits telomerase activity by reducing Cbf5 in human liver cancer stem cells. Mol Ther Nucleic Acids 2021;23:310-23. [PMID: 33425489 DOI: 10.1016/j.omtn.2020.11.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Kim GD. Ursolic Acid Decreases the Proliferation of MCF-7 Cell-Derived Breast Cancer Stem-Like Cells by Modulating the ERK and PI3K/AKT Signaling Pathways. Prev Nutr Food Sci 2021;26:434-44. [PMID: 35047440 DOI: 10.3746/pnf.2021.26.4.434] [Reference Citation Analysis]
3 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Reference Citation Analysis]
4 Borlak F, Reutzel-Selke A, Schirmeier A, Gogolok J, von Hoerschelmann E, Sauer IM, Pratschke J, Bahra M, Schmuck RB. Notch Signaling Pathway in Pancreatobiliary Tumors. Medicina (Kaunas) 2021;57:105. [PMID: 33498866 DOI: 10.3390/medicina57020105] [Reference Citation Analysis]
5 Mohan A, Raj Rajan R, Mohan G, Kollenchery Puthenveettil P, Maliekal TT. Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells. Front Cell Dev Biol 2021;9:668851. [PMID: 34150761 DOI: 10.3389/fcell.2021.668851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang PJ, Liu MD, Fan FY, Liu KX. A Study on Mesoporous Silica Loaded With Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma. Front Oncol 2021;11:665182. [PMID: 34268112 DOI: 10.3389/fonc.2021.665182] [Reference Citation Analysis]
7 Zhen X, Choi HS, Kim JH, Kim SL, Liu R, Yun BS, Lee DS. Machilin D, a Lignin Derived from Saururus chinensis, Suppresses Breast Cancer Stem Cells and Inhibits NF-κB Signaling. Biomolecules 2020;10:E245. [PMID: 32033472 DOI: 10.3390/biom10020245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Luo Y, Yin S, Lu J, Zhou S, Shao Y, Bao X, Wang T, Qiu Y, Yu H. Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment. Cancer Cell Int 2021;21:386. [PMID: 34284780 DOI: 10.1186/s12935-021-02085-6] [Reference Citation Analysis]
9 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Reference Citation Analysis]
10 Massa A, Varamo C, Vita F, Tavolari S, Peraldo-Neia C, Brandi G, Rizzo A, Cavalloni G, Aglietta M. Evolution of the Experimental Models of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2308. [PMID: 32824407 DOI: 10.3390/cancers12082308] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
11 Mao S, He J, Zhao Y, Liu T, Xie F, Yang H, Mao Y, Pang Y, Sun W. Bioprinting of patient-derived in vitro intrahepatic cholangiocarcinoma tumor model: establishment, evaluation and anti-cancer drug testing. Biofabrication 2020;12:045014. [PMID: 32599574 DOI: 10.1088/1758-5090/aba0c3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
12 Feng J, Zhu R, Yin Y, Wang S, Zhou L, Lv F, Zhao D. Re-Recognizing the Cellular Origin of the Primary Epithelial Tumors of the Liver. JHC 2021;Volume 8:1537-63. [DOI: 10.2147/jhc.s334935] [Reference Citation Analysis]
13 Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021;13:1113-34. [PMID: 34190581 DOI: 10.2217/imt-2021-0126] [Reference Citation Analysis]
14 Chae WO, Kim GD. Dioscin Decreases Breast Cancer Stem-like Cell Proliferation via Cell Cycle Arrest by Modulating p38 Mitogen-activated Protein Kinase and AKT/mTOR Signaling Pathways. J Cancer Prev 2021;26:183-94. [PMID: 34703821 DOI: 10.15430/JCP.2021.26.3.183] [Reference Citation Analysis]
15 Lee HY, Hong IS. Targeting Liver Cancer Stem Cells: An Alternative Therapeutic Approach for Liver Cancer. Cancers (Basel). 2020;12. [PMID: 32987767 DOI: 10.3390/cancers12102746] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel) 2021;13:558. [PMID: 33535621 DOI: 10.3390/cancers13030558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 25.0] [Reference Citation Analysis]
17 Sangsuwannukul T, Supimon K, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Wongkham S, Junking M, Yenchitsomanus PT. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. Int Immunopharmacol 2020;89:107069. [PMID: 33242709 DOI: 10.1016/j.intimp.2020.107069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cao L, Prithviraj P, Shrestha R, Sharma R, Anaka M, Bridle KR, Kannourakis G, Crawford DHG, Jayachandran A. Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study. J Clin Med 2021;10:2191. [PMID: 34069452 DOI: 10.3390/jcm10102191] [Reference Citation Analysis]
19 Dong B, Li S, Zhu S, Yi M, Luo S, Wu K. MiRNA-mediated EMT and CSCs in cancer chemoresistance. Exp Hematol Oncol 2021;10:12. [PMID: 33579377 DOI: 10.1186/s40164-021-00206-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Yapasert R, Lertprasertsuk N, Subhawa S, Poofery J, Sripanidkulchai B, Banjerdpongchai R. Antitumor Efficacy of the Herbal Recipe Benja Amarit against Highly Invasive Cholangiocarcinoma by Inducing Apoptosis both In Vitro and In Vivo. Int J Mol Sci 2020;21:E5669. [PMID: 32784671 DOI: 10.3390/ijms21165669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rizzo A, Ricci AD, Cusmai A, Acquafredda S, De Palma G, Brandi G, Palmiotti G. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. Current Oncology 2022;29:551-64. [DOI: 10.3390/curroncol29020050] [Reference Citation Analysis]
22 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
23 Huang X, Wu W, Yang W, Qing X, Shao Z. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma. Colloids Surf B Biointerfaces 2020;190:110891. [PMID: 32114271 DOI: 10.1016/j.colsurfb.2020.110891] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
24 Zhen X, Choi HS, Kim JH, Kim SL, Liu R, Ko YC, Yun BS, Lee DS. Caudatin Isolated from Cynanchum auriculatum Inhibits Breast Cancer Stem Cell Formation via a GR/YAP Signaling. Biomolecules 2020;10:E925. [PMID: 32570844 DOI: 10.3390/biom10060925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Liu Y. Targeting the non-canonical AKT-FOXO3a axis: A potential therapeutic strategy for oral squamous cell carcinoma. EBioMedicine 2019;49:6-8. [PMID: 31648985 DOI: 10.1016/j.ebiom.2019.10.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lu M, Qin X, Zhou Y, Li G, Liu Z, Geng X, Yue H. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Cell Death Dis 2021;12:72. [PMID: 33436545 DOI: 10.1038/s41419-020-03346-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Wang W, Sun Y, Li X, Shi X, Li Z, Lu X. Dihydroartemisinin Prevents Distant Metastasis of Laryngeal Carcinoma by Inactivating STAT3 in Cancer Stem Cells. Med Sci Monit 2020;26:e922348. [PMID: 32176678 DOI: 10.12659/MSM.922348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Jia M, Jia X, Zhang D, Liu W, Yi S, Li Z, Cong B, Ma C, Li S, Zhang J. CD2+ T-helper 17-like cells differentiated from a CD133+ subpopulation of non-small cell lung carcinoma cells promote the growth of lung carcinoma. Ann Transl Med 2021;9:687. [PMID: 33987385 DOI: 10.21037/atm-21-980] [Reference Citation Analysis]